Soleus Capital — 2024 Investments
1 investments dated 2024 · listed companies and verified rows first · show all
AltruBioaltrubio.comMay 2024 · $225M
AltruBio develops antibody-based therapeutics for immunological and inflammatory diseases, with clinical-stage candidates (ALTB-268 and ALTB-168) targeting conditions such as ulcerative colitis, psoriatic arthritis, psoriasis, and acute graft versus host disease.
BiotechHealthtech
Co-investorsaMoonDelos CapitalRA CapitalBiotechnology Value Fund
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.